Mycophenolate Mofetil Helped Prevent Vasculitis Relapses
A study found that adding this medication may benefit older adults experiencing a vasculitis relapse during rituximab maintenance.
Updated on Oct. 6, 2026 in Asthma
Live Poll
Should medical researchers prioritize testing lower-dose drug treatments to help reduce patient side effects?
A retrospective study published September 15, 2026, found that patients who relapsed while on rituximab therapy for ANCA-associated vasculitis experienced fewer second relapses when treated with mycophenolate mofetil. This approach may offer a new strategy for managing patients who face recurring symptoms during standard maintenance care.
Why it matters
Managing patients who experience a relapse while receiving rituximab maintenance therapy is a clinical challenge due to limited evidence. Identifying effective follow-up treatments could help improve long-term outcomes for those living with these complex autoimmune conditions.
This retrospective study of 17 patients with a median age of 76 compared clinical outcomes over a median follow-up of 28 months. Researchers observed no second relapses in those receiving 1000 mg of mycophenolate mofetil daily compared to those who did not receive the treatment.
The players
PLOS One
A peer-reviewed open-access scientific journal that publishes research across all areas of science and medicine.
The details
Mycophenolate mofetil acts as an immunosuppressant that may help stabilize the immune system in patients who have failed initial rituximab maintenance. Physicians in the study administered the drug at a daily dose of 1000 mg to manage the flare-ups after the first relapse. The researchers also monitored participants for serious infections, noting that those on the added therapy did not require hospitalizations for severe infections during the study period.
Timeline
The study was published online in PLOS One on September 15, 2026.
The median duration of patient follow-up was 28 months.
The median time to glucocorticoid discontinuation in the mycophenolate mofetil group was 3.8 months.
Health Landscape
Rituximab maintenance therapy is a cornerstone in the treatment of ANCA-associated vasculitis. This study explores a management strategy for cases where this standard approach is insufficient to prevent subsequent flares.
Patients dealing with ANCA-associated vasculitis who experience a relapse while on rituximab should discuss potential secondary treatments with their specialist. It is important to ask your physician about the risks and benefits of adding immunosuppressive agents like mycophenolate mofetil.
The takeaway
This study suggests that adding mycophenolate mofetil may offer a path to remission for older patients who experience a relapse on rituximab. If you are managing an autoimmune condition, keep a detailed log of your symptoms and any treatment changes to share with your rheumatologist.
Further reading
Learn more about managing chronic respiratory and autoimmune inflammation in our Asthma section.
More information
Review the full findings in the PLOS One study on AAV relapse.
Live Poll
Should medical researchers prioritize testing lower-dose drug treatments to help reduce patient side effects?
